4 results  1 of 1 

1 The Effect of Long-Term Sodium-Glucose Cotransporter 2 Inhibitor Treatment on Renal Function in Patients with Type 2 Diabetes
Jong Ha Baek, Tae Jung Oh, Ju-Young Moon, Taehee Kim, Seung Hyun Ko, Min Kyong Moon, Hyun Jung Kim, Dong Won Lee, Kyu Yeon Hur
J Korean Diabetes.2020;21(3):105-115.   Published online 2020 September 30     DOI: http://dx.doi.org/10.4093/jkd.2020.21.3.105
      
2 A Review of the Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Lean Body Mass in Humans
Jack Alistair Sargeant, Joseph Henson, James Adam King, Thomas Yates, Kamlesh Khunti, Melanie Jane Davies
Endocrinol Metab.2019;34(3):247-262.   Published online 2019 September 26     DOI: http://dx.doi.org/10.3803/EnM.2019.34.3.247
   
3 Case of hyperosmolar hyperglycemic state by a sodium-glucose cotransporter 2 inhibitor
In-Young Nho, Hae-Sung Kim, Nam-Kyu Kang, Myung-Won Lee, Soo-Kyung Kim, Seok-O Park
Kosin Med J.2018;33(3):402-408.   Published online 2018 December 31     DOI: http://dx.doi.org/10.7180/kmj.2018.33.3.402
      
4 Addition of Ipragliflozin to Metformin Treatment in Korean Patients with Type 2 Diabetes Mellitus: Subgroup Analysis of a Phase 3 Trial
Kyung-Wan Min, Bon Jeong Ku, Ji-Hyun Lee, Min-Seon Kim, Kyu-Jeung Ahn, Moon-Kyu Lee, Satoshi Kokubo, Satoshi Yoshida, Hyun-Ji Cho, Bong-Soo Cha
Diabetes Metab J.2017;41(2):135-145.   Published online 2017 January 11     DOI: http://dx.doi.org/10.4093/dmj.2017.41.2.135
      

 1 of 1